Zynerba Pharmaceuticals (NASDAQ:ZYNE) initiated a Phase 2 trial to assess the safety, tolerability and efficacy of Zygel for the treatment of autism spectrum disorder (ASD).
Zygel in a cannabidiol-based gel that provides controlled drug delivery into the bloodstream through the skin. The 14-week trial, known as BRIGHT, is an open-label multi-dose trial being conducted in children and adolescents with confirmed ASD.
In addition to ASD, Zynerba is developing Zygel for Fragile X syndrome, 22q deletion syndrome, and developmental and epileptic encephalopathies.
Zynerba expects to present topline data the BRIGHT study in the first half of 2020.
